• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Immunic Inc.

    1/10/24 9:00:03 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMUX alert in real time by email
    SC 13G 1 ea191414-13gsoleus3_immunic.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    IMMUNIC, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    4525EP101

    (CUSIP Number)

     

    January 8, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    **There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 589492107 has been assigned to the American Depositary Receipts (“ADRs”) of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “MREO.” Each ADR represents 5 Ordinary Shares.

     

     

     

     

     

     

    CUSIP NO. 4525EP101

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Private Equity Fund III, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,895,105 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,895,105 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,895,105 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.4% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

    FOOTNOTES

     

    (1) The shares reported in this row are owned directly by Soleus Private Equity Fund III, L.P. (“Soleus PE”). Soleus Private Equity GP III, LLC (“Soleus GP”) is the sole general partner of Soleus PE. Soleus GP holds voting and dispositive power over the shares held by Soleus PE. Soleus PE GP III, LLC is the sole manager of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus PE GP III, LLC. Each of Mr. Guy Levy, Soleus PE GP III, LLC and Soleus GP disclaims beneficial ownership of these securities held by Soleus PE and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or for any other purpose, except to the extent of their respective pecuniary interests therein.

      

    (2) This percentage is calculated based upon 89,896,669 shares of the common stock, par value $0.0001 per share, of the Issuer (“Common Stock”), outstanding following the completion of the offering of Common Stock and pre-funded warrants contemplated by that certain Securities Purchase Agreement dated as of January 4, 2024 by and among the Issuer and the investors parties thereto (the “Offering”).

     

    2

     

     

    CUSIP NO. 4525EP101

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Private Equity GP III, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,895,105 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,895,105 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,895,105 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.4% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1) The shares reported in this row are owned directly by Soleus PE. Soleus GP is the sole general partner of Soleus PE. Soleus GP holds voting and dispositive power over the shares held by Soleus PE. Soleus PE GP III, LLC is the sole manager of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus PE GP III, LLC.

      

    (2) This percentage is calculated based upon 89,896,669 shares of Common Stock outstanding of the Issuer after giving effect to the Offering.

     

    3

     

     

    CUSIP NO. 4525EP101

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus PE GP III, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,895,105 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,895,105 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,895,105 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.4% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1) The shares reported in this row are owned directly by Soleus PE. Soleus GP is the sole general partner of Soleus PE. Soleus GP holds voting and dispositive power over the shares held by Soleus PE. Soleus PE GP III, LLC is the sole manager of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus PE GP III, LLC.

     

    (2) This percentage is calculated based upon 89,896,669 shares of Common Stock outstanding of the Issuer after giving effect to the Offering.

     

    4

     

     

    CUSIP NO. 4525EP101

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Master Fund, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    2,397,902 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    2,397,902 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,397,902 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    2.7% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    FI

     

    FOOTNOTES

     

    (1) The shares reported in this row are owned directly by Soleus Capital Master Fund, L.P. (“Master Fund”). Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

      

    (2) This percentage is calculated based upon 89,896,669 shares of Common Stock outstanding of the Issuer after giving effect to the Offering.

     

    5

     

     

    CUSIP NO. 4525EP101

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    2,397,902 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    2,397,902 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,397,902 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    2.7% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1) The shares reported in this row are owned directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC.

     

    (2) This percentage is calculated based upon 89,896,669 shares of Common Stock outstanding of the Issuer after giving effect to the Offering.

     

    6

     

     

    CUSIP NO. 4525EP101

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Group, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    2,397,902 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    2,397,902 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,397,902 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    2.7% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1) The shares reported in this row are owned directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC.

      

    (2) This percentage is calculated based upon 89,896,669 shares of Common Stock outstanding of the Issuer after giving effect to the Offering.

     

    7

     

     

    CUSIP NO. 4525EP101

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Guy Levy

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,293,007 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,293,007 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,293,007 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.1% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    FOOTNOTES

     

    (1) 4,895,105 of the shares reported in this row are beneficially owned directly by Soleus PE and 2,397,902 of the shares reported in this row are beneficially owned directly by Master Fund.

     

    (2) This percentage is calculated based upon 89,896,669 shares of Common Stock outstanding of the Issuer after giving effect to the Offering.

     

    8

     

     

    Item 1.

     

      (a) Name of Issuer

     

    Immunic, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

     

    1200 Avenue of the Americas, Suite 200

    New York, NY 10036

     

    Item 2.

     

      (a) Name of Person(s) Filing

     

    Soleus Private Equity GP III, LLC

    Soleus Private Equity Fund III, L.P.

    Soleus PE GP III, LLC

    Soleus Capital Master Fund, L.P.

    Soleus Capital, LLC

    Soleus Capital Group, LLC

    Guy Levy

     

      (b) Address of Principal Business Office or, if none, Residence

     

    Soleus Private Equity GP III, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Private Equity Fund III, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus PE GP III, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital Master Fund, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital Group, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Guy Levy

    c/o Soleus Capital Management, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    9

     

     

      (c) Citizenship

     

    Soleus Private Equity GP III, LLC – Delaware

    Soleus Private Equity Fund III, L.P. – Delaware

    Soleus PE GP III, LLC – Delaware

    Soleus Capital Master Fund, L.P. – Cayman Islands

    Soleus Capital, LLC – Delaware

    Soleus Capital Group, LLC – Delaware

    Guy Levy – United States

     

      (d) Title of Class of Securities

     

    Common Stock, $0.0001 par value

     

      (e) CUSIP Number

     

    4525EP101

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐78c).
         
    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
         
    (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         
    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
         
    (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4. Ownership.

     

    Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G.

     

    As the general partner of Soleus PE, Soleus GP may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the securities held by Soleus PE. As the sole manager of Soleus GP, Soleus PE GP III, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or direct the disposition of the securities held by Soleus PE. As the sole managing member of Soleus PE GP III, LLC, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the securities held by Soleus PE.

     

    As the general partner of Master Fund, Soleus Capital, LLC may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the securities held by Master Fund. As the sole managing member of Soleus Capital, LLC, Soleus Capital Group, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or direct the disposition of the securities held by Master Fund. As the sole managing member of Soleus Capital Group, LLC, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the securities held by Master Fund.

     

    Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that Mr. Levy, Soleus PE GP III, LLC, Soleus GP, Soleus Capital, LLC or Soleus Capital Group, LLC is the beneficial owner of the securities of the Issuer referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of their respective pecuniary interest therein, and such beneficial ownership is expressly disclaimed.

     

    10

     

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    11

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: January 10, 2024 Soleus Private Equity Fund III, L.P.
       
      By: Soleus Private Equity GP III, LLC, its General Partner
       
      By: Soleus PE GP III, LLC, its Manager
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: January 10, 2024 Soleus Private Equity GP III, LLC
       
      By: Soleus PE GP III, LLC, its Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: January 10, 2024 Soleus PE GP III, LLC
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: January 10, 2024 Soleus Capital Master Fund, L.P.
       
      By: Soleus Capital, LLC, its General Partner
       
      By: Soleus Capital Group, LLC, its Managing Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: January 10, 2024 Soleus Capital, LLC
       
      By: Soleus Capital Group, LLC, its Managing Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: January 10, 2024 Soleus Capital Group, LLC
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: January 10, 2024 /s/ Guy Levy
      Name: Guy Levy

     

    Footnotes:

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    12

     

     

    EXHIBIT A

    JOINT FILING AGREEMENT

     

    Soleus Private Equity Fund III, L.P., a Delaware limited partnership, Soleus Private Equity GP III, LLC, a Delaware limited liability company, Soleus PE GP III, LLC, a Delaware limited liability company, Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934, as amended.

     

    It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other party unless such party knows or has reason to believe that such information is inaccurate.

     

    It is understood and agreed that a copy of this Agreement shall be attached as an exhibit to the statement on Schedule 13G, and any amendments hereto, filed on behalf of each of the parties hereto.

     

    Date: January 10, 2024 Soleus Private Equity Fund III, L.P.
       
      By: Soleus Private Equity GP III, LLC, its General Partner
       
      By: Soleus PE GP III, LLC, its Manager
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: January 10, 2024 Soleus Private Equity GP III, LLC
       
      By: Soleus PE GP III, LLC, its Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: January 10, 2024 Soleus PE GP III, LLC
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: January 10, 2024 Soleus Capital Master Fund, L.P.
       
      By: Soleus Capital, LLC, its General Partner
       
      By: Soleus Capital Group, LLC, its Managing Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: January 10, 2024 Soleus Capital, LLC
       
      By: Soleus Capital Group, LLC, its Managing Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: January 10, 2024 Soleus Capital Group, LLC
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: January 10, 2024 /s/ Guy Levy
      Name: Guy Levy

     

     

     
    Get the next $IMUX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMUX

    DatePrice TargetRatingAnalyst
    11/7/2025$3.00Buy
    Roth Capital
    9/29/2025$13.00Buy
    Chardan Capital Markets
    3/25/2025Outperform
    William Blair
    11/25/2024$10.00Buy
    H.C. Wainwright
    9/9/2024$5.00Outperform
    Leerink Partners
    8/27/2024$6.00Buy
    B. Riley Securities
    10/21/2022$5.00Outperform → Mkt Perform
    SVB Leerink
    9/19/2022$26.00Buy
    H.C. Wainwright
    More analyst ratings

    $IMUX
    SEC Filings

    View All

    Immunic Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - IMMUNIC, INC. (0001280776) (Filer)

    1/6/26 4:05:54 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - IMMUNIC, INC. (0001280776) (Filer)

    1/5/26 5:00:47 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Immunic Inc.

    SCHEDULE 13G - IMMUNIC, INC. (0001280776) (Subject)

    12/8/25 11:45:04 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

    – Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity – – CALLIPER Subset Data Demonstrate Reductions in EBV-Specific T-Cell Receptor Sequences, Underlining Broad-Spectrum Antiviral Effects of Vidofludimus Calcium – NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the presentation of additional data from its phase 2 CALLIPER trial evaluating lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressi

    2/4/26 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Highlights 2025 Accomplishments and Upcoming Milestones

    – Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 – – Phase 2 CALLIPER Data Showed Vidofludimus Calcium Reduced 24-Week Confirmed Disability Worsening and Increased 24-Week Confirmed Disability Improvement Across Progressive Multiple Sclerosis and Its Subtypes, Reinforcing the Drug's Direct Neuroprotective Mechanism of Action – – Long-Term Open-Label Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Showed Low Rates of Confirmed Disability Worsening Events and Favorable Long-Term Safety and Tolerability – – U.S. Patent Allowed for Dose Strengths

    1/7/26 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

    NEW YORK, Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025 at 9:35 am ET at the 8th Annual Evercore ISI Healthcare Conference, taking place December 2-4, 2025 in Coral Gables, FL. A webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations. Dr. Vitt and Jason Tardio, President and Chief Operating Officer of Immunic, will also partici

    11/26/25 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Immunic with a new price target

    Roth Capital initiated coverage of Immunic with a rating of Buy and set a new price target of $3.00

    11/7/25 8:30:20 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Immunic with a new price target

    Chardan Capital Markets initiated coverage of Immunic with a rating of Buy and set a new price target of $13.00

    9/29/25 9:57:47 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Immunic

    William Blair initiated coverage of Immunic with a rating of Outperform

    3/25/25 8:27:26 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Whaley Glenn

    4 - IMMUNIC, INC. (0001280776) (Issuer)

    7/18/25 4:06:30 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Chairman Nash Duane

    4 - IMMUNIC, INC. (0001280776) (Issuer)

    7/18/25 4:06:15 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and Director Vitt Daniel

    4 - IMMUNIC, INC. (0001280776) (Issuer)

    7/18/25 4:05:56 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: President and COO Tardio Jason bought $9,884 worth of shares (12,512 units at $0.79) (SEC Form 4)

    4/A - IMMUNIC, INC. (0001280776) (Issuer)

    6/20/25 5:16:19 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: CEO and Director Vitt Daniel bought $11,550 worth of shares (15,000 units at $0.77), increasing direct ownership by 107% to 29,000 units (SEC Form 4)

    4/A - IMMUNIC, INC. (0001280776) (Issuer)

    6/20/25 5:15:45 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Nash Duane bought $16,694 worth of shares (20,000 units at $0.83), increasing direct ownership by 125% to 36,032 units (SEC Form 4)

    4 - IMMUNIC, INC. (0001280776) (Issuer)

    6/16/25 5:00:19 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immunic Inc.

    SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

    11/14/24 5:33:45 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immunic Inc.

    SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

    11/14/24 12:30:35 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immunic Inc.

    SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

    11/14/24 6:58:13 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Leadership Updates

    Live Leadership Updates

    View All

    Immunic Highlights 2024 Accomplishments and Upcoming Milestones

    – Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 – – Strengthened Management Team and Board of Directors with Key Hires – – Announced a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered,

    1/7/25 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

    – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Simona Skerjanec, M.Pharm, MBA, a thought-leader in brain health with decades of experience in drug development and commercialization, to its board of directors, effective July 22, 2024. Over a nea

    7/24/24 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Appoints Jason Tardio as Chief Operating Officer and President

    – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President, Program Management & Clinical Development Operations, Promoted to Chief Development Officer – NEW YORK, July 9, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that seasoned biopharmaceutical executive, Jason Tardio, will be joining the company as Chief Operating Officer and President, effective July 12, 2024. In the newly created role, Mr. Tardio will lead in

    7/9/24 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMUX
    Financials

    Live finance-specific insights

    View All

    Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

    – 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – – NfL Effect in Non-Active Subpopulation Reinforces Vidofludimus Calcium's Neuroprotective Potential – – Brain Volume Data of the Full 467 CALLIPER Patient Cohort Expected in April 2025 – – Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing – – Conference Call and Webcast to be Held Tomorrow, October 10, 2023 at 8:00 am ET – NEW YORK, Oct. 9, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chr

    10/9/23 4:01:00 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

    – Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients' Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption – – Corroborates Hypothesized Ability of IMU-856 to Renew Gut Wall and Restore Gut Health – – No Safety or Tolerability Issues Detected – – Conference Call and Webcast to be Held Today, May 4, 2023 at 8:00 am ET – NEW YORK, May 4, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive results fro

    5/4/23 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

    – 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of Vidofludimus Calcium Demonstrated Statistically Significant Rates of Clinical Remission (p=0.0358) and Endoscopic Healing (p=0.0259) at Week 50 – – To Focus Resources on High Performing Vidofludimus Calcium and IMU-856 Programs, Immunic Decided to Deprioritize Izumerogant (IMU-935) Program – – Conference Call and Webcast to be Held today, April 5, 2023 at 8:00 am ET – NEW YORK, April 5, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi

    4/5/23 6:30:00 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care